Global Information Inc. would like to present a new market research report, "Autoimmune Disease Therapeutics to 2016 - Targets, Technologies, Therapies, Markets and Opportunities" by Greystone Research Associates.
The new study is designed to provide drug company decision makers, drug delivery developers, device designers, healthcare marketers, and supply chain participants with a detailed understanding of the economics, technologies, treatment segments, and commercial opportunities for the treatment of autoimmune conditions.
Evolving Disease Targets and Therapeutic Strategies
Previously considered an untreatable disease segment, the last decade has seen advances in therapeutic drugs that have opened up the field of autoimmune disease therapeutics to a growing number of new treatment options. Furthering this trend, numerous pipeline candidates targeting segments for the immune system cascade are now winding their way through the clinical development process. For autoimmune sector participants, successfully navigating this therapeutics landscape is presenting new challenges. Perhaps more than any other disease segment, autoimmune conditions and the companies that market treatments for them are benefitting from the potential for expanded indications. Because of the individual genetic variability underlying the incidence and severity of autoimmune symptoms, regional variations in the market for autoimmune therapeutics can be significant. This variability is compounded by differences in treatment protocols and cultural factors, which combine to make alliance partnerships with regional players of increasing importance.
Greystone Researchs new report provides a comprehensive evaluation and analysis of the technology, products and participants providing the driving force behind the evolving autoimmune disease therapeutics healthcare segment.